VHL and breast carcinoma: The designed molecule ZL216 promoted the formation of nucleolin-ZL216-VHL ternary complex by using AS1411 as a ligand for binding to nucleolin, which potently eliminated nucleolin in breast cancer cells in vitro and in vivo, and inhibited proliferation and migration of breast cancer cells in vitro [110].